

FINDING BALANCE

in the Treatment of **Bipolar I Disorder** and **Schizophrenia**.

About the Program

Despite a wealth of antipsychotic treatment options in Canada, many important gaps persist in the management of both bipolar I disorder (BPI) and schizophrenia (SZ).

Please join your peers for an informative and interactive session focusing on the addition of a new agent to the antipsychotic armamentarium.

At the conclusion of the session, participants will be able to:

- Identify current unmet needs for patients with:
- Explain similarities, differences, and potential clinical implications of cariprazine's pharmacologic characteristics relative to previously approved 2nd and 3rd-generation antipsychotics.
- ♦ Describe the efficacy and safety of cariprazine in clinical trials in:
- Define the place of cariprazine in clinical practice among patients with:

RSVP to	
Email	Phone
Ву	

DATE TIME SPEAKER

LOCATION

Program developed by

HOWARD MARGOLESE MD, CM, MSc, FRCPC Montreal, QC

DIANE MCINTOSH BSc Pharm, MD, FRCPC

Vancouver, BC

ROGER MCINTYRE MD, FRCPC Toronto, ON

RIC PROCYSHYN MSc, Pharm. D, PhD Vancouver, BC

This program is supported by AbbVie Corporation. In compliance with the Innovative Medicines Canada Code of Ethical Practices, this invitation is extended to Healthcare Professionals only. This is a personal and non-transferable invitation, any total or partial reproduction, alteration, sharing or improper use of this content without prior authorization from AbbVie is expressly prohibited. All rights reserved.

This material is protected by Copyright and other intellectual property protection laws.